BFO
IDXX icon

Boston Family Office’s Idexx Laboratories IDXX Stock Holding History

Boston Family Office’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.8M Sell
26,344
-711
-3% -$456K 0.98% 32
2025
Q4 		$18.3M Sell
27,055
-612
-2% -$417K 1.16% 26
2025
Q3 		$17.7M Sell
27,667
-260
-0.9% -$158K 1.12% 27
2025
Q2 		$15M Sell
27,927
-731
-3% -$350K 0.99% 31
2025
Q1 		$12M Buy
28,658
+1,277
+5% +$554K 0.85% 34
2024
Q4 		$11.3M Buy
27,381
+473
+2% +$207K 0.78% 38
2024
Q3 		$13.6M Sell
26,908
-19
-0.1% -$9.23K 0.92% 35
2024
Q2 		$13.1M Sell
26,927
-133
-0.5% -$66.8K 0.95% 33
2024
Q1 		$14.6M Sell
27,060
-126
-0.5% -$68.9K 1.05% 29
2023
Q4 		$15.1M Sell
27,186
-260
-0.9% -$122K 1.13% 29
2023
Q3 		$12M Sell
27,446
-625
-2% -$312K 0.98% 30
2023
Q2 		$14.1M Sell
28,071
-1,513
-5% -$725K 1.08% 30
2023
Q1 		$14.8M Sell
29,584
-306
-1% -$146K 1.19% 27
2022
Q4 		$12.2M Buy
29,890
+163
+0.5% +$63.3K 1.01% 35
2022
Q3 		$9.69M Buy
29,727
+5,109
+21% +$1.88M 0.86% 39
2022
Q2 		$8.63M Buy
24,618
+3,959
+19% +$1.61M 0.72% 45
2022
Q1 		$11.3M Buy
20,659
+295
+1% +$155K 0.8% 40
2021
Q4 		$13.4M Sell
20,364
-173
-0.8% -$109K 0.87% 38
2021
Q3 		$12.8M Buy
20,537
+89
+0.4% +$59.8K 0.93% 36
2021
Q2 		$12.9M Sell
20,448
-111
-0.5% -$61.3K 0.92% 37
2021
Q1 		$10.4M Sell
20,559
-3,110
-13% -$1.56M 0.78% 44
2020
Q4 		$11.8M Sell
23,669
-2,053
-8% -$919K 0.91% 37
2020
Q3 		$10.1M Sell
25,722
-86
-0.3% -$31.8K 0.92% 39
2020
Q2 		$8.52M Sell
25,808
-105
-0.4% -$30.4K 0.83% 42
2020
Q1 		$6.28M Buy
25,913
+58
+0.2% +$15.1K 0.74% 43
2019
Q4 		$6.75M Sell
25,855
-70
-0.3% -$18.4K 0.64% 49
2019
Q3 		$7.05M Sell
25,925
-432
-2% -$120K 0.73% 46
2019
Q2 		$7.26M Sell
26,357
-135
-0.5% -$33.3K 0.75% 46
2019
Q1 		$5.92M Buy
26,492
+1,373
+5% +$283K 0.64% 51
2018
Q4 		$4.67M Buy
25,119
+2,075
+9% +$425K 0.58% 53
2018
Q3 		$5.75M Sell
23,044
-55
-0.2% -$13.4K 0.61% 52
2018
Q2 		$5.03M Buy
23,099
+1,005
+5% +$207K 0.57% 62
2018
Q1 		$4.23M Buy
22,094
+108
+0.5% +$19.9K 0.48% 69
2017
Q4 		$3.44M Buy
21,986
+993
+5% +$156K 0.38% 83
2017
Q3 		$3.26M Buy
20,993
+3,585
+21% +$567K 0.37% 80
2017
Q2 		$2.81M Sell
17,408
-1,335
-7% -$217K 0.33% 90
2017
Q1 		$2.9M Buy
18,743
+163
+0.9% +$22.5K 0.36% 85
2016
Q4 		$2.18M Sell
18,580
-586
-3% -$66.9K 0.28% 98
2016
Q3 		$2.16M Sell
19,166
-327
-2% -$34.5K 0.28% 100
2016
Q2 		$1.81M Sell
19,493
-188
-1% -$16.1K 0.23% 110
2016
Q1 		$1.54M Buy
19,681
+3,000
+18% +$216K 0.2% 122
2015
Q4 		$1.22M Sell
16,681
-2,445
-13% -$174K 0.17% 131
2015
Q3 		$1.42M Buy
19,126
+2,800
+17% +$201K 0.2% 124
2015
Q2 		$1.05M Buy
16,326
+4,100
+34% +$284K 0.13% 144
2015
Q1 		$944K Buy
12,226
+1,500
+14% +$117K 0.12% 154
2014
Q4 		$795K Sell
10,726
-46
-0.4% -$3.23K 0.1% 163
2014
Q3 		$635K Hold
10,772
– – 0.08% 183
2014
Q2 		$719K Sell
10,772
-50
-0.5% -$3.18K 0.09% 177
2014
Q1 		$657K Sell
10,822
-150
-1% -$8.94K 0.09% 178
2013
Q4 		$584K Buy
10,972
+300
+3% +$15.8K 0.08% 179
2013
Q3 		$532K Buy
10,672
+432
+4% +$20.8K 0.08% 184
2013
Q2 		$459K Buy
+10,240
New +$447K 0.07% 187

Other funds holding IDXX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Boston Family Office's IDXX Position: Q1 2026 in Review

Boston Family Office reduced its Idexx Laboratories (IDXX) stake by 2.6% in Q1 2026, selling an estimated $456K and leaving 26,344 shares worth $14.8M. The position accounts for 0.98% of the portfolio, ranked #32.

Boston Family Office first reported a position in IDXX in Q2 2013 and has held it in 52 quarters since. The position peaked at $18.3M in Q4 2025. 1,311 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.

  • Boston Family Office held 26,344 shares of Idexx Laboratories worth $14.8M as of Q1 2026.
  • Boston Family Office sold 711 Idexx Laboratories shares in Q1 2026, an estimated $456K.
  • Idexx Laboratories made up 0.98% of Boston Family Office's portfolio in Q1 2026, its #32 holding.
  • Boston Family Office first reported a position in Idexx Laboratories in Q2 2013 and has held it in 52 quarters since.
  • Boston Family Office's Idexx Laboratories position peaked at $18.3M in Q4 2025.
  • 1,311 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.

Based on Boston Family Office's 13F filing for Q1 2026, filed 13 May 2026.